TY - JOUR
T1 - Assessment and treatment of cardiovascular risk in prediabetes
T2 - Impaired glucose tolerance and impaired fasting glucose
AU - DeFronzo, Ralph A.
AU - Abdul-Ghani, Muhammad
N1 - Funding Information:
Publication of this supplement was supported by funding from Novo Nordisk. Editorial support was provided by Dr. Ruth Kleinpell and Mary Lou Briglio.
PY - 2011/8/2
Y1 - 2011/8/2
N2 - Individuals with impaired glucose tolerance (IGT) and/or impaired fasting glucose (IFG) are at high risk, not only to develop diabetes mellitus, but also to experience an adverse cardiovascular (CV) event (myocardial infarction, stroke, CV death) later in life. The underlying pathophysiologic disturbances (insulin resistance and impaired β-cell function) responsible for the development of type 2 diabetes are maximally/near maximally expressed in subjects with IGT/IFG. These individuals with so-called prediabetes manifest all of the same CV risk factors (dysglycemia, dyslipidemia, hypertension, obesity, physical inactivity, insulin resistance, procoagulant state, endothelial dysfunction, inflammation) that place patients with type 2 diabetes at high risk for macrovascular complications. The treatment of these CV risk factors should follow the same guidelines established for patients with type 2 diabetes, and should be aggressively followed to reduce future CV events.
AB - Individuals with impaired glucose tolerance (IGT) and/or impaired fasting glucose (IFG) are at high risk, not only to develop diabetes mellitus, but also to experience an adverse cardiovascular (CV) event (myocardial infarction, stroke, CV death) later in life. The underlying pathophysiologic disturbances (insulin resistance and impaired β-cell function) responsible for the development of type 2 diabetes are maximally/near maximally expressed in subjects with IGT/IFG. These individuals with so-called prediabetes manifest all of the same CV risk factors (dysglycemia, dyslipidemia, hypertension, obesity, physical inactivity, insulin resistance, procoagulant state, endothelial dysfunction, inflammation) that place patients with type 2 diabetes at high risk for macrovascular complications. The treatment of these CV risk factors should follow the same guidelines established for patients with type 2 diabetes, and should be aggressively followed to reduce future CV events.
UR - http://www.scopus.com/inward/record.url?scp=79961009650&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79961009650&partnerID=8YFLogxK
U2 - 10.1016/j.amjcard.2011.03.013
DO - 10.1016/j.amjcard.2011.03.013
M3 - Review article
C2 - 21802577
AN - SCOPUS:79961009650
SN - 0002-9149
VL - 108
SP - 3B-24B
JO - American Journal of Cardiology
JF - American Journal of Cardiology
IS - 3 SUPPL.
ER -